Financial Performance - The company's operating revenue for 2022 was ¥2,122,705,317.42, representing a 2.15% increase compared to ¥2,077,988,730.16 in 2021[6]. - The net profit attributable to shareholders decreased by 19.63% to ¥75,543,369.47 in 2022 from ¥93,992,380.84 in 2021[6]. - The basic earnings per share fell by 28.35% to ¥0.0968 in 2022, down from ¥0.1351 in 2021[6]. - The total assets increased by 10.85% to ¥4,505,582,532.92 at the end of 2022, compared to ¥4,064,525,859.70 at the end of 2021[6]. - The company's cash flow from operating activities decreased by 18.63% to ¥124,471,194.04 in 2022 from ¥152,978,505.57 in 2021[6]. - The weighted average return on equity decreased by 1.72 percentage points to 3.09% in 2022 from 4.81% in 2021[6]. - The company reported a net profit of -¥26,914,451.49 in Q4 2022, contrasting with profits in the first three quarters[23]. - The company reported a net profit attributable to shareholders of 75.54 million yuan, a decrease of 19.63% compared to the previous year[40]. - The overall revenue for the reporting period increased by CNY 16.83 million, a growth of 2.34% compared to the same period last year[49]. - The net profit for the reporting period decreased by CNY 8.53 million, a decline of 33.60% year-on-year[49]. Revenue Breakdown - Revenue from veterinary chemical drugs was 983.93 million yuan, a decrease of 7.71%, accounting for 46.35% of total revenue[40]. - Revenue from veterinary biological products increased by 13.19% to 330.17 million yuan, making up 15.55% of total revenue[40]. - The environmental business saw a revenue increase of 25.07%, reaching 107.58 million yuan, which accounted for 5.07% of total revenue[40]. - The revenue from the agricultural processing industry increased by CNY 55.02 million, a growth of 10.76% year-on-year[55]. - Domestic sales accounted for 65.61% of total revenue, increasing by 7.84% compared to the previous year[56]. - Direct sales revenue reached CNY 1,578,151,290, a year-on-year increase of 29.06%[57]. - The revenue from Pharmgate Inc. increased by CNY 88.06 million, a growth of 22.88% compared to the previous year[52]. - The revenue from the environmental business increased by CNY 28.04 million, representing an 18.51% growth compared to the previous year[51]. Cost and Expenses - The company's operating costs reached 1,508.91 million CNY, a year-on-year increase of 5.75%, with veterinary chemical drugs accounting for 46.90% of total operating costs[43]. - The gross profit margin decreased by 2.42 percentage points compared to the previous year due to the increase in operating costs outpacing revenue growth[43]. - The total cost of raw materials for veterinary chemical drugs was approximately 400.69 million, accounting for 56.61% of the total operating costs, showing a slight decrease of 0.18% compared to 2021[63]. - The total sales expenses increased by 6.70% to approximately 130.72 million in 2022, compared to 122.51 million in 2021[68]. - Research and development expenses rose by 13.89% to approximately 82.28 million in 2022, compared to 72.25 million in 2021, reflecting increased investment in vaccine projects and new product development[68]. Market and Competition - The veterinary medicine industry is experiencing increased concentration, with the top 31 companies accounting for 80.4% of total sales in the biological products sector[29]. - The company is facing intensified competition and opportunities in the veterinary medicine market due to regulatory changes and increased foreign investment[30]. - The company is actively expanding into the pet medicine sector, with plans to increase product variety and scope in the future[33]. - The company is focusing on strategic adjustments in product structure to enhance product value and expand business scale[46]. Research and Development - The company has a strong emphasis on research and development, with four major technology platforms for vaccine production and significant advancements in product upgrades[37]. - R&D investment increased by 39.78% to ¥122,010,847.05 in 2022, representing 5.75% of operating revenue[71]. - The number of R&D personnel rose to 252, a 4.13% increase from 2021, with a notable increase in PhD holders by 20%[71]. - The company is focusing on new product development in veterinary vaccines, with several new products expected to be launched in the coming years[33]. Corporate Governance - The company maintains independent operations and governance, with no interference from controlling shareholders in decision-making processes[126]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[126]. - The company has established a robust financial management system, including independent accounting and tax reporting[130]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[127]. Environmental Responsibility - The company adheres to various environmental standards, including GB13271-2014J for boiler emissions and GB37823-2019 for pharmaceutical industry emissions[172]. - The company has implemented real-time monitoring of emissions for various pollutants, ensuring adherence to environmental standards[176]. - The company has established a zero discharge wastewater project, ensuring that treated water meets the required pollution discharge standards[176]. - In 2022, the company invested CNY 1.353 million in environmental governance facilities and paid CNY 0.6981 million in environmental protection tax[178]. Future Outlook - The company plans to continue focusing on product development and market expansion to mitigate the impact of market fluctuations[58]. - The company aims to become a technology-driven, leading animal health company within the next 5-10 years[115]. - The company anticipates a revenue growth target of 20% for the next fiscal year, driven by new product launches and market penetration strategies[89]. - The company plans to enhance its supply chain efficiency, targeting a 15% reduction in operational costs by 2024[137].

证券代码：002688 证券简称：金河生物 公告编号:2023-013 金河生物科技股份有限公司 关于举行2022年年度报告网上业绩说明会的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）定于2023年5月10日（星 期三）下午15:00至17:00在全景网举办2022年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次年度业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 9 日 15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问 题征集专题页面。敬请广大投资者通过全景网系统提交您所关注的问题，便于 公司在业绩说明会上对投资者普遍关注的问题进行回答，提升此次业绩说明会 的针对性。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广 ...

Group 1: Company Overview - The company, Jinhe Biological, has significant sales in both domestic and international markets, with foreign market revenue accounting for 50,983.09 million in 2014, representing a substantial portion of its main business income [1] - The main products are used as feed additives to promote animal production and prevent diseases, and as purified hydrochloride for treating animal diseases [3] Group 2: Product Characteristics - The key features of feed-grade gold mycin include: (1) mature production technology with high efficacy and relatively low cost; (2) broad antibacterial spectrum effective against both Gram-negative and Gram-positive bacteria; (3) no cross-use in humans and animals, avoiding cross-resistance; (4) high safety with low-dose long-term use not causing drug residues; (5) minimal compatibility issues with other feed additives or veterinary drugs [3] Group 3: Strategic Acquisitions - The acquisition of Panfield's operating assets aims to utilize its sales channels to strengthen the company's market position and serve as a strategic development reserve for future expansion [4] Group 4: Future Development Goals - The company envisions becoming a world-leading animal health product enterprise, focusing on consolidating its advantages in biological fermentation and drug feed additives, while actively developing new products in the field of novel veterinary biological products [4]

Group 1: Company Competitive Advantages - The company has over 20 years of experience in biological fermentation production, making it one of the largest producers of feed-grade gold mycelium globally [1] - Key competitive advantages include technological superiority, regional advantages, customer and market network marketing advantages, product quality advantages, and brand advantages [2] Group 2: Target Consumer Groups - The main consumer groups for the company's products include domestic and international animal health product companies, feed companies, and poultry and livestock farms [2] Group 3: Stock Issuance Progress - As of November 26, 2015, the China Securities Regulatory Commission approved the company's application for a non-public stock issuance, with further steps pending the receipt of formal approval documents [2] Group 4: Strategic Development Goals - The company's strategic goal is to create a world-leading animal health product enterprise, consolidating its advantages in biological fermentation and drug feed additives while innovating and expanding into new veterinary biological products [3]

Group 1: Company Overview - The company, Jinhe Biological Technology Co., Ltd., has over 20 years of development and primarily engages in the production and sales of feed additives, with a focus on feed-grade chlortetracycline [2][3] - Jinhe is the largest global producer of feed-grade chlortetracycline [3] Group 2: Product Functions - Feed-grade chlortetracycline is used to promote animal growth, improve feed conversion rates, and prevent animal diseases. It can reduce mortality rates and increase weight gain and feed conversion rates when fed at low doses [3] Group 3: Fundraising and Financials - The total amount raised from the non-public offering of shares is 47.34 million yuan, with the net proceeds intended to supplement the company's working capital after deducting issuance costs. Approval from the China Securities Regulatory Commission is still pending [3][4] Group 4: Raw Material Impact - The cost of corn, which constitutes approximately 30% to 50% of the company's main business costs, is influenced by various factors including climate, national corn reserve policies, and supply-demand relationships [4]

Group 1: Company Product Advantages - The main advantages of the company's feed additive product,金霉素, include broad-spectrum antibacterial effects, low cost, high safety, and no residue [4] - The product has a low risk of cross-infection between humans and animals, and fewer drug interactions [4] Group 2: Market Performance - The company has signed a five-year procurement agreement with Zoetis in the U.S. for金霉素, effective until December 31, 2019, with good execution so far [4] - Domestic demand for金霉素 is expected to grow due to the intensification of pig farming and standardized drug use [4] Group 3: Industry Barriers - Key barriers to entering the feed additive industry include strict production licensing regulations, technical barriers, financial barriers, and brand reliability [5] Group 4: Future Development Plans - The company aims to become a world-leading animal health product enterprise, focusing on enhancing its advantages in biological fermentation and feed additives [5] - Plans include developing new products, extending the product line, expanding business scale, and enhancing global market influence [5] - The company is also exploring opportunities in environmental protection, particularly in wastewater treatment, to create new profit growth points [5]

Group 1: Company Overview - The company operates in the fields of veterinary drug additives, animal vaccines, animal health products, corn starch processing, and environmental technology [2] - The vision is to create a world-leading animal health product enterprise, enhancing core competitiveness and expanding business scale [2] Group 2: Future Development Plans - The company aims to strengthen its advantages in biological fermentation and drug feed additives while actively developing new products to increase added value [2] - Plans to expand into wastewater treatment as a new profit growth point [2][3] Group 3: Environmental Technology - Inner Mongolia Jinhe Environmental Technology Co., Ltd. focuses on high-concentration industrial wastewater treatment, with a daily treatment capacity of 10,000 tons [3] - The company employs a third-party governance model to improve treatment efficiency and reduce pollution control costs [3] Group 4: Financial Information - The lock-up period for the non-public stock issuance is three years, with no performance commitments or leverage involved [3] Group 5: Product Information - The main function of feed-grade gold mycin is to promote animal growth, improve feed conversion rates, and prevent animal diseases [3]

Group 1: Market Demand and Growth Drivers - The main drivers for the growth of the feed-grade gold mycin industry include an increase in breeding volume, higher per-animal usage, and rising prices. The domestic market has significant long-term growth potential due to intensified farming practices and improved awareness of medication among farmers [2][3]. - The expansion into emerging foreign markets is expected to create substantial demand growth for gold mycin [3]. Group 2: Company Developments and Strategic Positioning - After acquiring Panfield, the subsidiary Pharmaway has shifted its focus to directly producing and selling animal health products in the U.S. market, including gold mycin and other feed additives [3]. - The company successfully completed a non-public stock issuance in February 2016, with future financing activities to be determined based on strategic planning and development [4]. Group 3: Future Plans and Environmental Initiatives - The company aims to become a world-leading animal health product enterprise, enhancing its competitive edge in biopharmaceuticals and feed additives while actively developing new products and expanding its market influence [4]. - The subsidiary Inner Mongolia Jinhe Environmental Technology Co., Ltd. focuses on high-concentration industrial wastewater treatment, currently processing 10,000 tons of wastewater daily, with plans for nationwide business expansion [5]. Group 4: Acquisitions and Product Diversification - The acquisition of a 67% stake in Hangzhou Jianliang Veterinary Biological Products Co., Ltd. is significant due to the stringent regulatory environment for veterinary biological products, allowing the company to quickly enter the vaccine sector and diversify its product offerings [6].

Group 1: Financial Performance and Contracts - The company is currently undergoing a private placement, with announcements to be made according to regulatory procedures [1][2] - The cash flow situation has been disclosed in the company's financial reports [2] - The gross profit margin and net profit margin have increased compared to last year due to better vaccine sales [2][3] Group 2: Product Development and Market Strategy - The company is actively developing vaccines, with a focus on products like the dual vaccine for pigs and the brucellosis vaccine, expected to be registered by mid-next year [5][12] - The company plans to expand its production capacity for gentamicin, with a new project of 60,000 tons expected to be operational by the second half of next year [9][12] - The company is also preparing to launch a pet care division, focusing on deworming products [10][12] Group 3: Market Conditions and Challenges - The company has faced challenges due to rising raw material prices, leading to a 15% price increase for gentamicin [7] - The impact of the pandemic on sales was significant in 2020, but recovery is underway, with domestic sales of gentamicin gradually increasing [7][12] - The company is monitoring the competitive landscape, particularly regarding alternative products being developed by competitors [4][9] Group 4: Investor Relations and Communication - The company emphasizes transparency and timely communication with investors, adhering to legal disclosure requirements [11] - There is a commitment to improving investor relations and providing detailed updates on product registrations and market strategies [11][12] - The company is open to suggestions for enhancing investor communication and engagement [11]

Group 1: Company Growth Strategy - The company aims to achieve a revenue of approximately 5 billion by 2025, with a net profit of 600 million and a market value of 20 billion [1][5][9] - The strategic plan was developed in 2020 and focuses on the animal health industry, with agricultural product processing and environmental treatment as auxiliary sectors [1][5] Group 2: Stock Performance and Market Communication - The company's stock price has been low for several years, attributed to various factors including market conditions and internal communication issues [2][3] - A share buyback plan has been initiated to boost stock prices, with future measures to be considered based on market conditions [2][3][6] Group 3: Financial Performance and Dividends - The company did not distribute cash dividends in 2021 due to poor performance influenced by upstream and downstream industry factors, and to allocate funds for the share buyback plan [4][9] - The company is focused on maximizing shareholder interests and aims for long-term returns [4][9] Group 4: Product Pricing and Market Conditions - The price of the company's gold mildew product is currently around 19,000 yuan per ton, showing an increase compared to last year [5][8] - The company is preparing to launch a brucellosis vaccine, expected to receive certification in 4-6 months, with production planned for the fourth quarter [8][9] Group 5: Competitive Positioning - The main competitors in the chemical drug sector include companies like Chia Tai Animal Health, with the company holding advantages in production capacity, market scale, and technology [5][9] - The company aims to expand its vaccine business, targeting a revenue of over 700 million by 2025, with a projected budget of 340 million for 2022, reflecting a growth of around 20% [8][9]